Table 3. HER-2 expression in metastases and primary tumors assessed with IHC and Dual-ISH and HER-3 expression as assessed by IHC.

IHC/ISH score for HER-2 expression	0	1+	2- (ISH-)	2+ (ISH+)	3+
HER-2 expression and gene amplification in metastases (n = 208)	133 (63.9%)	33 (15.9%)	25 (12.0%)	8 (3.8%)	9 (4.3%)
HER-2 expression and gene amplification in primary tumors (n = 22)	3 (13.6%)	5 (22.7%)	10 (45.5%)	3 (13.6%)	1 (4.5%)
IHC score for HER-3 expression	0	1+	2+		3+
HER-3 expression in metastases (n = 208)	51 (24.5%)	1 (0.5%)	63 (30.3%)		93 (44.7%)
HER-3 expression in primary tumors (n = 22)	5 (22.7%)	1 (4.5%)	2 (9.1%)		14 (63.6%)